MTE #6: New Hepatitis B Virus and Hepatitis D Virus Treatments Including Drugs in Development (Ticketed)

The recent wealth of new clinical trial data addressing the treatment of persons living with hepatitis B virus (HBV) moninfection, and HBV and hepatitis D virus (HDV) coinfection has fueled excitement among clinicians regarding the prospect of cures for HBV infection and HBV/HDV coinfection. This expert session focuses on new treatments for HBV monoinfection and HBV/HDV coinfection including: Capsid assembly modulators (CAMs; eg, pevifoscorvir) Small interfereing RNA (SiRNA; eg, elebsiran) and antisense oligonucleotides (ASO; eg, bepirovirsen) Monoclonal hepatitis B surface (HBs) antibodies (eg, tobevibart) Gene editing nucleases (eg, PBGENE-HBV) Other novel therapies Discussion leaders present a representative case and integrate new clinical trial data to illustrate the role of newer therapies for persons living with HBV or HBV/HDV infection.